| Multiple newly identified loci associated with prostate cancer susceptibility | Nature Genetics | 2008 | 722 |
| Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven | Journal of Clinical Oncology | 2008 | 713 |
| Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises | Current Opinion in Pharmacology | 2008 | 439 |
| A new formalism for reference dosimetry of small and nonstandard fields | Medical Physics | 2008 | 391 |
| European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I | European Urology | 2008 | 373 |
| Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients | Breast Cancer Research and Treatment | 2008 | 257 |
| Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer | Clinical Radiology | 2008 | 215 |
| Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial | Lancet, The | 2008 | 210 |
| Genome-wide association studies in cancer | Human Molecular Genetics | 2008 | 196 |
| European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II | European Urology | 2008 | 194 |
| A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer | Clinical Cancer Research | 2008 | 177 |
| Platinum-based chemotherapy in triple-negative breast cancer | Annals of Oncology | 2008 | 167 |
| EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy | European Journal of Nuclear Medicine and Molecular Imaging | 2008 | 156 |
| Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study | Annals of Oncology | 2008 | 152 |
| Adapting IMRT delivery fraction-by-fraction to cater for variable intrafraction motion | Physics in Medicine and Biology | 2008 | 131 |
| Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics | Journal of Medical Genetics | 2008 | 129 |
| Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial | Gene Therapy | 2008 | 117 |
| Disease-specific complications of chronic lymphocytic leukemia | Hematology American Society of Hematology Education Program | 2008 | 115 |
| Supportive care needs of men living with prostate cancer in England: a survey | British Journal of Cancer | 2008 | 111 |
| The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI | European Journal of Nuclear Medicine and Molecular Imaging | 2008 | 111 |
| Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial | Journal of the National Cancer Institute | 2008 | 110 |
| Prognostic false-positivity of the sentinel node in melanoma | Nature Clinical Practice Oncology | 2008 | 109 |
| Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype | British Journal of Cancer | 2008 | 107 |
| Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging | International Journal of Radiation Oncology Biology Physics | 2008 | 105 |
| Therapeutic target metabolism observed using hyperpolarized 15N choline | Journal of the American Chemical Society | 2008 | 104 |
